Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

Douglas J Harrison1, Cindy L Schwartz2

  • 1MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. djharrison@mdanderson.org.

Current Treatment Options in Oncology
|April 10, 2017
PubMed
Summary

Osteosarcoma treatment needs improvement. Immunotherapy, like mifamurtide (L-MTP-PE), shows promise in improving survival for osteosarcoma patients, though it awaits FDA approval.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.

Molecular cancer therapeutics·2026
Same author

Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.

Pediatric blood & cancer·2025
Same author

TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.

Cancers·2025
Same author

Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group.

International journal of radiation oncology, biology, physics·2025
Same author

PET Response and Outcome in Low-Risk Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1.

Pediatric blood & cancer·2025
Same author

Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.

JAMA oncology·2025

Area of Science:

  • Pediatric Oncology
  • Bone Cancer Research
  • Chemotherapy Resistance

Background:

  • Osteosarcoma is the most common bone cancer in children and adolescents.
  • Current treatment, including neoadjuvant chemotherapy (MAP regimen) and surgery, has not significantly improved outcomes due to chemotherapy resistance and micrometastases.
  • Novel therapeutic strategies are urgently needed to combat this aggressive cancer.

Purpose of the Study:

  • To review the current treatment landscape for osteosarcoma.
  • To highlight the limitations of existing therapies, particularly chemotherapy resistance.
  • To explore the potential of novel agents, including immunotherapy, to improve patient survival.

Main Methods:

  • Review of current osteosarcoma treatment protocols, including neoadjuvant chemotherapy (methotrexate, doxorubicin, cisplatin - MAP) and surgical resection.
Keywords:
ChemotherapyImmunotherapyL-MTP-PEMAPOsteosarcomaTargeted therapy

Related Experiment Videos

  • Analysis of prognostic factors, such as histologic response to neoadjuvant chemotherapy.
  • Evaluation of emerging immunotherapies, specifically liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE).

    • Main Results:

    • The standard MAP chemotherapy regimen followed by surgery is the backbone of osteosarcoma treatment.
    • Histologic response to neoadjuvant chemotherapy is prognostic, but augmenting adjuvant therapy has not improved outcomes.
    • Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), a macrophage activator, demonstrated improved 10-year survival in localized and metastatic osteosarcoma patients in Europe.

    Conclusions:

    • Despite aggressive multimodal therapy, osteosarcoma outcomes remain poor due to treatment resistance and recurrence.
    • Immunotherapy, exemplified by L-MTP-PE (mifamurtide), offers a promising avenue for improving survival rates in osteosarcoma.
    • Further research into novel targeted therapies and broader immunotherapy applications is critical for advancing osteosarcoma treatment.